Calcitriol Monotherapy for X-Linked Hypophosphatemia
Calcitriol Monotherapy for X-Linked Hypophosphatemia: Effects on Mineral Ions, Growth and Skeletal Parameters
Sponsor: Massachusetts General Hospital
A EARLY_PHASE1 clinical study on Hypophosphatemic Rickets and Hypophosphatemic Rickets, X-Linked Dominant, this trial is ongoing. The trial is conducted by Massachusetts General Hospital and has accumulated 9 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2025 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting EARLY_PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Recruiting EARLY_PHASE1
-
Apr 2022 — Apr 2024 [monthly]
Recruiting EARLY_PHASE1
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Recruiting EARLY_PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting EARLY_PHASE1
-
Sep 2019 — Oct 2020 [monthly]
Recruiting EARLY_PHASE1
-
Dec 2018 — Sep 2019 [monthly]
Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
For direct contact, visit the study record on ClinicalTrials.gov .